Literature DB >> 31469566

Cyanine-Gemcitabine Conjugates as Targeted Theranostic Agents for Glioblastoma Tumor Cells.

Zhengyang Jiang1, Kathryn Pflug2, Syed Muhammad Usama1, Dacheng Kuai1, Xin Yan1, Raquel Sitcheran2, Kevin Burgess1.   

Abstract

A small subset of heptamethine dyes (cyanine-7 or Cy7) share an intriguing characteristic: preferential tumor accumulation and retention. These dyes absorb in the near-infrared (NIR) region (above 750 nm) and perform active targeting to deliver therapeutic and toxic cargoes to various tumor models in vivo. In this work, four heptamethines 1 were synthesized, which have a gemcitabine fragment attached to the meso-position of the Cy7 core. Theranostic agent 1a was discovered that localized in glioblastoma tumor cells, has absorption maxima in NIR region, and showed similar therapeutic effect to gemcitabine but at one-third the molar dose.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31469566      PMCID: PMC7050787          DOI: 10.1021/acs.jmedchem.9b01147

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  33 in total

1.  A practical guide to evaluating colocalization in biological microscopy.

Authors:  Kenneth W Dunn; Malgorzata M Kamocka; John H McDonald
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-05       Impact factor: 4.249

2.  The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.

Authors:  G Stehle; H Sinn; A Wunder; H H Schrenk; S Schütt; W Maier-Borst; D L Heene
Journal:  Anticancer Drugs       Date:  1997-08       Impact factor: 2.248

3.  Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

Authors:  Stijn L W Koolen; Petronella O Witteveen; Robert S Jansen; Marlies H G Langenberg; Roelien H Kronemeijer; Annemarie Nol; Ignacio Garcia-Ribas; Sophie Callies; Karim A Benhadji; Christopher A Slapak; Jos H Beijnen; Emile E Voest; Jan H M Schellens
Journal:  Clin Cancer Res       Date:  2011-07-13       Impact factor: 12.531

4.  H-gemcitabine: a new gemcitabine prodrug for treating cancer.

Authors:  Madhuri Dasari; Abhinav P Acharya; Dongin Kim; Seungjun Lee; Sungmun Lee; Jeanne Rhea; Ross Molinaro; Niren Murthy
Journal:  Bioconjug Chem       Date:  2012-12-26       Impact factor: 4.774

5.  Near IR heptamethine cyanine dye-mediated cancer imaging.

Authors:  Xiaojian Yang; Chunmeng Shi; Rong Tong; Weiping Qian; Haiyen E Zhau; Ruoxiang Wang; Guodong Zhu; Jianjun Cheng; Vincent W Yang; Tianmin Cheng; Maged Henary; Lucjan Strekowski; Leland W K Chung
Journal:  Clin Cancer Res       Date:  2010-04-21       Impact factor: 12.531

6.  A concise synthesis of the Pennsylvania Green fluorophore and labeling of intracellular targets with O6-benzylguanine derivatives.

Authors:  Laurie F Mottram; Ewa Maddox; Markus Schwab; Florent Beaufils; Blake R Peterson
Journal:  Org Lett       Date:  2007-08-17       Impact factor: 6.005

7.  Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis.

Authors:  Sandhya Kiran Apparaju; Gary A Gudelsky; Pankaj B Desai
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-19       Impact factor: 3.333

8.  Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.

Authors:  Swati Kushal; Weijun Wang; Vijaya Pooja Vaikari; Rajesh Kota; Kevin Chen; Tzu-Shao Yeh; Niyati Jhaveri; Susan L Groshen; Bogdan Z Olenyuk; Thomas C Chen; Florence M Hofman; Jean C Shih
Journal:  Oncotarget       Date:  2016-03-22

Review 9.  Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements.

Authors:  David G Levitt; Michael D Levitt
Journal:  Int J Gen Med       Date:  2016-07-15

10.  Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.

Authors:  Ping Zhu; Xianglin L Du; Guangrong Lu; Jay-Jiguang Zhu
Journal:  Oncotarget       Date:  2017-07-04
View more
  11 in total

Review 1.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

2.  Quantification of Cellular Drug Biodistribution Addresses Challenges in Evaluating in vitro and in vivo Encapsulated Drug Delivery.

Authors:  Christopher B Rodell; Paige Baldwin; Bianca Fernandez; Ralph Weissleder; Srinivas Sridhar; J Matthew Dubach
Journal:  Adv Ther (Weinh)       Date:  2020-12-16

Review 3.  Fluorescent kinase inhibitors as probes in cancer.

Authors:  Syed Muhammad Usama; Bosheng Zhao; Kevin Burgess
Journal:  Chem Soc Rev       Date:  2021-07-22       Impact factor: 60.615

4.  Synthesis and Biological Evaluation of Genistein-IR783 Conjugate: Cancer Cell Targeted Delivery in MCF-7 for Superior Anti-Cancer Therapy.

Authors:  Yang Guan; Yi Zhang; Juan Zou; Li-Ping Huang; Mahendra D Chordia; Wei Yue; Jin-Jun Wu; Dong-Feng Pan
Journal:  Molecules       Date:  2019-11-14       Impact factor: 4.411

5.  Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows in vitro and in vivo antitumor efficacy toward the treatment of nasopharyngeal cancer cells.

Authors:  Dongmei Liu; Wenguang Zhang; Xinju Liu; Rongliang Qiu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 6.  Design Principles Governing the Development of Theranostic Anticancer Agents and Their Nanoformulations with Photoacoustic Properties.

Authors:  Stavroula G Kyrkou; Eirinaios I Vrettos; Dimitris Gorpas; Timothy Crook; Nelofer Syed; Andreas G Tzakos
Journal:  Pharmaceutics       Date:  2022-02-04       Impact factor: 6.321

Review 7.  The use of radiosensitizing agents in the therapy of glioblastoma multiforme-a comprehensive review.

Authors:  Niklas Benedikt Pepper; Walter Stummer; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2022-05-03       Impact factor: 4.033

Review 8.  The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors.

Authors:  Elizabeth Cooper; Peter J Choi; William A Denny; Jiney Jose; Mike Dragunow; Thomas I-H Park
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

9.  Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients.

Authors:  Ying Xiao; Yuewen Gao; Fajuan Li; Zhihe Deng
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 10.  Potential of Cyanine Derived Dyes in Photodynamic Therapy.

Authors:  Natalia Lange; Wojciech Szlasa; Jolanta Saczko; Agnieszka Chwiłkowska
Journal:  Pharmaceutics       Date:  2021-05-31       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.